Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

터너증후군 환자에서 최종 성인키에 영향을 미치는 인자들에 대한 연구

Factors Affecting Final Adult Height in Patients with Turner Syndrome

  • 김재현 (서울대학교 의과대학 소아과학교실) ;
  • 이성수 (서울대학교 의과대학 소아과학교실) ;
  • 홍수영 (서울대학교 의과대학 소아과학교실) ;
  • 정혜림 (서울대학교 의과대학 소아과학교실) ;
  • 신충호 (서울대학교 의과대학 소아과학교실) ;
  • 양세원 (서울대학교 의과대학 소아과학교실)
  • Kim, Jae Hyun (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Sung Soo (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Hong, Su Young (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Chung, Hye Rim (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Shin, Choong Ho (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Yang, Sei Won (Department of Pediatrics, Seoul National University College of Medicine)
  • 투고 : 2004.09.09
  • 심사 : 2004.10.08
  • 발행 : 2005.02.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : 터너증후군 환자들에게서 성장지연 및 저신장은 흔한 문제로 이의 치료로 성장호르몬이 투여되고 있으나 이에 대한 연구 결과들은 일치되지 않은 결과들을 보고하고 있다. 저자들은 터너증후군 환자에서 성장 호르몬 투여 및 기타 인자들이 최종 성인 키에 어떤 영향을 미치는 지에 대해 알아보고자 본 연구를 시행하였다. 방 법 : 1985년부터 1998년까지 서울대학교 어린이병원 소아과에서 터너증후군으로 진단 받은 환자들 중에서 성인에 도달한 환자들을 대상으로, 최종 성인키와 최종 성인키의 SD score 및 이에 영향을 미칠 수 있는 인자들과의 연관성을 후향적으로 분석하였다. 결 과 : 대상 환자는 모두 60명으로 이 가운데 성장호르몬 치료를 받은 환자들은 48명, 성장호르몬 치료를 받지 않은 환자는 모두 12명이었다. 성장호르몬 치료군의 치료 시작시 평균 역연령은 $12.2{\pm}2.7$세, 평균 골연령은 $10.3{\pm}2.5$세, 평균 키는 $127.5{\pm}10.1cm$, 평균 키의 SD score는 $-3.1{\pm}1.1$였으며, 비치료군과 비교하여 평균 역연령과, 평균 키의 SD score를 제외하고 통계적으로 유의한 차이는 없었다. 성장호르몬 치료군에서 성장 호르몬의 평균 투여 기간은 35.8개월(범위 : 4-120개월)이었으며, 평균 용량은 $0.8{\pm}0.2IU/kg/wk$이었고, 평균 최종 성인키는 $146.9{\pm}5.8cm$이었고, 비치료군의 평균 최종 성인키는 $141.1{\pm}4.8cm$였고, 치료군과 비치료군 사이에 최종 성인키의 평균 SD score를 비교한 결과는 각각 $-2.7{\pm}1.2$와 $-3.8{\pm}1.0$로서 치료군에서 유의하게 높았다(P<0.05). 성장호르몬 치료군에서 치료 기간 중의 평균 성장 속도는 $5.6{\pm}2.0cm/yr$으로서 이는 치료 시작 전의 성장 속도인 $3.4{\pm}1.3cm/yr$과 비교하였을 때 통계적으로 유의하게 증가되었다(P<0.05). 성장호르몬 치료군에서 최종 성인키에 영향을 미치는 일반적인 인자에 대하여 분석하였을 때 출생시의 체중, 부모의 키, 중간부모키, 진단시(혹은 성장호르몬 치료 시작시) 역연령과 골연령, 골연령의 지연, 성장호르몬의 용랑, 치료 기간 등은 모두 최종 성인키와 연관이 없었고, 치료 시작시 키의 SD score가 클수록 최종 성인키의 SD score가 컸다(P<0.05, r=0.55). 결 론 : 터너증후군 환자에서 성장호르몬 치료를 시행한 군에서 평균 성장 속도가 치료 전보다 증가하였고, 최종 성인키도 비치료군과 비교하였을 때 유의하게 증가하였다. 터너증후군의 최종 성인키에 영향을 미치는 인자에는 성장호르몬 치료 시작시의 키의 SD score가 있다.

Purpose : Short stature is one of the characteristic features of Turner syndrome. We investigated the factors affecting final adult height(FAH) in patients with Turner syndrome. Methods : The study group was comprised of 60 patients who were diagnosed with Turner syndrome by chromosomal study and clinical phenotypes and attained FAH. Data were obtained from retrospective review of the medical records. We analyzed the factors influencing FAH in growth hormone(GH) treated and GH untreated groups. Results : Sixty patients were enrolled; 48 patients received GH treatment, and 12 patients did not. Mean duration of GH treatment was 35.8 months(range 4 to 120 months), and mean dosage of GH was $0.8{\pm}0.2IU/kg/wk$ in GH treated group. Mean growth velocity was $5.6{\pm}2.0cm/yr$, which was significantly higher than that during pretreatment period. In the GH treated group, mean chronological age, bone age, mean height, and height standard deviation(SD) score at GH treatment were $12.2{\pm}2.7yr$ $10.3{\pm}2.5yr$ $127.5{\pm}10.1cm$ and $-3.1{\pm}1.1$, respectively. In the GH treated group, the mean FAH and SD score of FAH were $146.9{\pm}5.8cm$ and $-2.7{\pm}1.2$, respectively, which showed significant differences compared with those of the GH untreated group. Analyzing the factors affecting FAH in GH-treated patients, only the SD score of height at the time of treatment was significantly related to FAH. Conclusion : GH treatment leads to an increment in FAH in patients with Turner syndrome. Average FAH gain was as much as 5.8 cm. SD score of height at the time of GH treatment was the only factor influencing FAH.

키워드

참고문헌

  1. Turner HH. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 1938;23:566-74 https://doi.org/10.1210/endo-23-5-566
  2. Warburton D, Kline J, Stein Z, Susser M. Monosomy X : a chromosomal anomaly associated with young maternal age. Lancet 1980;1:167-9
  3. Sperling MA. Pediatric endocrinology. 2nd ed. Philadelphia : Saunders 2002:519-64
  4. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54-63 https://doi.org/10.1038/ng0597-54
  5. Chung SC, Park MJ, Kim DH. Final adult height in patients with Turner syndrome. J Kor Soc Pediatr Endocrinol 1997;2:60-70
  6. Shin JH, Kho CW, Kim DH, Kim JD, Kim HS, Kim HS, et al. Growth curve for patients with Turner syndrome. J Kor Soc Pediatr Endocrinol 1998;3:1-6
  7. Dacou-Voutetakis C, Karavanaki-Karanassiou K, Petrou V, Georgopoulos N, Maniati-Christidi M, Mavrou A. The growth pattern and final height of girls with Turner syndrome with and without human growth hormone treatment. Pediatrics 1998;101:663-8 https://doi.org/10.1542/peds.101.4.663
  8. Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child 1985;60:932-5 https://doi.org/10.1136/adc.60.10.932
  9. Wilton P. Growth hormone treatment in girls with Turner's syndrome. A review of the literature. Acta Paediatr Scand 1987;76:193-200 https://doi.org/10.1111/j.1651-2227.1987.tb10447.x
  10. Van den Broeck J, Massa GG, Attanasio A, Matranga A, Chaussain JL, Price DA, et al. Final height after long-term growth hormone treatment in Turner syndrome. European Study Group. J Pediatr 1995;127:729-35 https://doi.org/10.1016/S0022-3476(95)70161-3
  11. Chu CE, Paterson WF, Kelnar CJ, Smail PJ, Greene SA, Donaldson MD. Variable effect of growth hormone on growth and final adult height in Scottish patients with Turner's syndrome. Acta Paediatr 1997;86:160-4 https://doi.org/10.1111/j.1651-2227.1997.tb08858.x
  12. Betts PR, Butler GE, Donaldson MD, Dunger DB, Johnston DI, Kelnar CJ, et al. A decade of growth hormone treatment in girls with Turner syndrome in the UK. Arch Dis Child 1999;80:221-5 https://doi.org/10.1136/adc.80.3.221
  13. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88:1119-25 https://doi.org/10.1210/jc.2002-021171
  14. Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, et al. Growth hormone therapy of Turner's syndrome : beneficial effect on adult height. J Pediatr 1998;132: 319-24 https://doi.org/10.1016/S0022-3476(98)70452-4
  15. Johnston DI, Betts P, Dunger D, Barnes N, Swift PG, Buckler JM, et al. A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome : near final height analysis. Arch Dis Child 2001;84: 76-81 https://doi.org/10.1136/adc.84.1.76
  16. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome : results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 2002;87:2033-41 https://doi.org/10.1210/jc.87.5.2033
  17. Shin JH, Kho CW, Kim DH, Kim JD, Kim HS, Kim HS, et al. Growth hormone therapy in girls with Turner syndrome; results of the Korean Turner Study Group. J Kor Soc Pediatr Endocrinol 1998;3:151-6
  18. Ford CE, Jones KW, Polani PE, DE Almeida JC, Briggs JH. A sex-chromosome anomaly in a case of gonadal dysgenesis (Turner's syndrome). Lancet 1959;1:711-3
  19. Palmer CG, Reichmann A. Chromosomal and clinical findings in 110 females with Turner syndrome. Hum Genet 1976;35:35-49 https://doi.org/10.1007/BF00295617
  20. Sarkar R, Marimuthu KM. Association between the degree of mosaicism and the severity of syndrome in Turner mosaics and Klinefelter mosaics. Clin Genet 1983;24:420-8 https://doi.org/10.1111/j.1399-0004.1983.tb00097.x
  21. Wyss D, DeLozier CD, Daniell J, Engel E. Structural anomalies of the X chromosome : personal observation and review of non-mosaic cases. Clin Genet 1982;21:145-59 https://doi.org/10.1111/j.1399-0004.1982.tb00752.x
  22. Goldman B, Polani PE, Daker MG, Angell RR. Clinical and cytogenetic aspects of X-chromosome deletions. Clin Genet 1982;21:36-52 https://doi.org/10.1111/j.1399-0004.1982.tb02077.x
  23. Hall JG, Gilchrist DM. Turner syndrome and its variants. Pediatr Clin North Am 1990;37:1421-40 https://doi.org/10.1016/S0031-3955(16)37018-3
  24. Ranke MB, Grauer ML. Adult height in Turner syndrome : results of a multinational survey 1993. Horm Res 1994;42: 90-4 https://doi.org/10.1159/000184154
  25. Ranke MB, Pfluger H, Rosendahl W, Stubbe P, Enders H, Bierich JR, et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr 1983; 141:81-8 https://doi.org/10.1007/BF00496795
  26. Kim DH, Lee BC, Yang SW, Chung YY. Clinical effects of Eutropin(recombinant human growth hormone) in patients with Turner syndrome. J Kor Soc Pediatr Endocrinol 1998; 3:172-83
  27. Saenger P. Clinical review 48 : The current status of diagnosis and therapeutic intervention in Turner's syndrome. J Clin Endocrinol Metab 1993;77:297-301 https://doi.org/10.1210/jc.77.2.297
  28. Carel JC, Mathivon L, Gendrel C, Ducret JP, Chaussain JL. Near normalization of final height with adapted doses of growth hormone in Turner's syndrome. J Clin Endocrinol Metab 1998;83:1462-6 https://doi.org/10.1210/jc.83.5.1462
  29. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment : results of a randomized doseresponse trial. J Clin Endocrinol Metab 1999;84:4607-12 https://doi.org/10.1210/jc.84.12.4607
  30. Jung MH, Hwang JS, Kim EY, Yang SW. Factors affecting final adult height in Turner syndrome. J Kor Soc Pediatr Endocrinol 1999;4:64-70
  31. Rochiccioli P, David M, Malpuech G, Colle M, Limal JM, Battin J, et al. Study of final height in Turner's syndrome : ethnic and genetic influences. Acta Paediatr 1994;83:305-8 https://doi.org/10.1111/j.1651-2227.1994.tb18099.x